Article
Endocrinology & Metabolism
Shuhui You, Chengcheng Gong, Yi Li, Yizhao Xie, Yumeng Li, Yannan Zhao, Biyun Wang
Summary: In HoR-positive MBC, patients with low and zero HER2 expression have similar clinical characteristics and respond similarly to endocrine treatment, but the chemotherapy effect is worse in the HER2-low patients. Moreover, the transformation of HER2 status from primary to metastatic lesions may have potential influence on chemotherapy outcomes.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Oncology
Yaping Yang, Junwei Li, Yajing Liu, Ying Zhong, Wei Ren, Yujie Tan, Zifan He, Chenchen Li, Jie Ouyang, Qiugen Hu, Yunfang Yu, Herui Yao
Summary: This study developed and validated a combined radiomic-clinical model using preoperative multiparametric MRI to predict endocrine resistance in non-metastatic breast cancer patients, showing superior performance compared to clinical and radiomic models alone in both training and validation cohorts.
Article
Gastroenterology & Hepatology
James L. Buxbaum, Martin Freeman, Stuart K. Amateau, Jean M. Chalhoub, Nayantara Coelho-Prabhu, Madhav Desai, Sherif E. Elhanafi, Nauzer Forbes, Larissa L. Fujii-Lau, Divyanshoo R. Kohli, Richard S. Kwon, Jorge D. Machicado, Neil B. Marya, Swati Pawa, Wenly H. Ruan, Sunil G. Sheth, Nikhil R. Thiruvengadam, Nirav C. Thosani, Bashar J. Qumseya
Summary: This guideline document, prepared by the American Society for Gastrointestinal Endoscopy, aims to provide best practice recommendations based on scientific evidence and considering various factors. However, it acknowledges that clinical decision-making is complex and guidelines cannot substitute a clinician's judgment. Clinical decisions should consider the clinician's experience, local expertise, available resources, and patient values. The document should not be used as a legal standard or in support of medical complaints, legal proceedings, and/or litigation.
GASTROINTESTINAL ENDOSCOPY
(2023)
Review
Oncology
Eunice Yoojin Lee, Dae-Won Lee, Kyung-Hun Lee, Seock-Ah Im
Summary: Hormone receptor-positive (HR+) breast cancer is the most common subtype with a favorable prognosis. Endocrine therapy, targeting steroid hormone signaling, is the main treatment option. The discovery of cyclin-dependent kinase 4/6 inhibitors has greatly improved the treatment outcome of advanced HR+ breast cancer. Additionally, targeted therapy, inhibitors, antibody-drug conjugates, and immunotherapeutic agents have expanded the available therapeutic options.
CANCER RESEARCH AND TREATMENT
(2023)
Article
Oncology
Jian Zhang, Yanchun Meng, Biyun Wang, Leiping Wang, Jun Cao, Zhonghua Tao, Ting Li, Wenqing Yao, Xichun Hu
Summary: The LORDSHIPS study investigated the safety and efficacy of a novel oral triplet combination of dalpiciclib, pyrotinib, and letrozole in patients with HER2-positive, hormone receptor-positive metastatic breast cancer. The results showed promising potential for this combination therapy.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Francesco Schettini, Mario Giuliano, Fabiola Giudici, Benedetta Conte, Pietro De Placido, Sergio Venturini, Carla Rognoni, Angelo Di Leo, Mariavittoria Locci, Guy Jerusalem, Lucia Del Mastro, Fabio Puglisi, PierFranco Conte, Michelino De Laurentiis, Lajos Pusztai, Mothaffar F. Rimawi, Rachel Schiff, Grazia Arpino, Sabino De Placido, Aleix Prat, Daniele Generali
Summary: A meta-analysis on first-/second-line ET +/- TT for HR+/HER2-negative MBC showed that combination strategies were more effective than single-agent ET, with CDK4/6-inhibitors + ET being the most effective regimen. Single agent ET demonstrated comparable efficacy with ET+TT combinations in non-visceral and endocrine sensitive diseases, while mTORi-based combinations and PI3Ki + ET showed valid therapeutic options in endocrine-resistant and PIK3CA-mutant tumors. These results reinforce international treatment guidelines and can assist in therapeutic decision-making.
Article
Gastroenterology & Hepatology
Divyanshoo R. Kohli, Stuart K. Amateau, Madhav Desai, Srinath Chinnakotla, M. Edwyn Harrison, Jean M. Chalhoub, Nayantara Coelho-Prabhu, Sherif E. Elhana, Nauzer Forbes, Larissa L. Fujii-Lau, Richard S. Kwon, Jorge D. Machicado, Neil B. Marya, Swati Pawa, Wenly Ruan, Sunil G. Sheth, Nikhil R. Thiruvengadam, Nirav C. Thosani, Bashar J. Qumseya
Summary: This clinical practice guideline provides evidence-based strategies for managing biliary strictures in liver transplant recipients. The guideline covers the role of different interventions and diagnostic modalities, such as ERCP, percutaneous transhepatic biliary drainage, cSEMSs, multiple plastic stents, and MRCP. It also discusses the administration of antibiotics during ERCP. Recommendations include the use of ERCP as the initial intervention and cSEMSs as the preferred stent for extrahepatic strictures, the use of MRCP for unclear diagnoses or intermediate probability of a stricture, and the administration of antibiotics when biliary drainage cannot be ensured during ERCP.
GASTROINTESTINAL ENDOSCOPY
(2023)
Article
Oncology
Melanie Royce, Christy L. Osgood, Anup K. Amatya, Mallorie H. Fiero, C. J. George Chang, Tiffany K. Ricks, Krithika A. Shetty, Jeffrey Kraft, Junshan Qiu, Pengfei Song, Rosane Charlab, Jingyu Yu, Kathryn E. King, Anshu Rastogi, Brian Janelsins, Wendy C. Weinberg, Kathleen Clouse, Vicky Borders-Hemphill, Lindsey Brown, Candace Gomez-Broughton, Zhong Li, Thuy Thanh Nguyen, Zhihao Qiu, Anh-Thy Ly, Suyoung Chang, Tingting Gao, Chi-Ming Tu, Bellinda King-Kallimanis, William F. Pierce, Kelly Chiang, Clara Lee, Kirsten B. Goldberg, John K. Leighton, Shenghui Tang, Richard Pazdur, Julia A. Beaver, Laleh Amiri-Kordestani
Summary: Margetuximab-cmkb in combination with chemotherapy was granted regular FDA approval for the treatment of HER2-positive metastatic breast cancer patients who have received two or more prior anti-HER2 regimens. The SOPHIA study demonstrated that margetuximab had a longer median progression-free survival compared to trastuzumab when both were combined with chemotherapy. Infusion-related reactions were reported as important safety signals associated with margetuximab plus chemotherapy.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Harold Burstein, Angela R. DeMichele, Mark Somerfield, N. Lynn Henry
Summary: ASCO Rapid Recommendations Updates revise selected ASCO guideline recommendations in response to new and practice-changing data. These updates are based on evidence reviews and follow ASCO's Guideline Methodology Manual. The aim is to promptly disseminate updated recommendations to enhance cancer care decisions for healthcare professionals and the public.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Juliana Navarro-Yepes, Nicole M. Kettner, Xiayu Rao, Cassandra Santaella Bishop, Tuyen N. Bui, Hannah F. Wingate, Akshara Singareeka Raghavendra, Yan Wang, Jing Wang, Aysegul A. Sahin, Funda Meric-Bernstam, Kelly K. Hunt, Senthil Damodaran, Debu Tripathy, Khandan Keyomarsi
Summary: CDK4/6 inhibitors combined with endocrine therapy are the standard treatment for HR-positive, HER2-negative metastatic breast cancer. However, resistance to these inhibitors remains a clinical problem. Different CDK4/6 inhibitors may have distinct mechanisms of resistance, and targeting specific pathways can delay disease progression.
Review
Oncology
Ran Ran, Yingying Ma, Hui Wang, Jin Yang, Jiao Yang
Summary: HR+/HER2+ metastatic breast cancer is a unique subtype of breast cancer. Combination regimens and endocrine therapy can provide long-term disease control, but accurately identifying the subset of patients who can benefit from de-chemotherapy treatment strategy is challenging.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Jinmei Zhou, Xuexue Wu, Huiqiang Zhang, Xiaobo Wang, Yang Yuan, Shaohua Zhang, Zefei Jiang, Tao Wang
Summary: This study aims to analyze the efficacy and safety of Tucidinostat combined with endocrine therapy in HR-positive and HER2-negative breast cancer patients after progression on CDK4/6 inhibitors. The preliminary results show that Tucidinostat combined with endocrine therapy may be an optional sequential strategy for patients with HR+/HER2-advanced breast cancer that has progressed on CDK4/6 inhibitors, especially for those with lower tumor burden and fewer prior palliative treatments.
Article
Oncology
Cheryl L. Rock, Cynthia A. Thomson, Kristen R. Sullivan, Carol L. Howe, Lawrence H. Kushi, Bette J. Caan, Marian L. Neuhouser, Elisa Bandera, Ying Wang, Kimberly Robien, Karen M. Basen-Engquist, Justin C. Brown, Kerry S. Courneya, Tracy E. Crane, David O. Garcia, Barbara L. Grant, Kathryn K. Hamilton, Sheri J. Hartman, Stacey A. Kenfield, Maria Elena Martinez, Jeffrey A. Meyerhardt, Larissa Nekhlyudov, Linda Overholser, Alpa Patel, Bernardine M. Pinto, Mary E. Platek, Erika Rees-Punia, Colleen K. Spees, Susan M. Gapstur, Marjorie L. McCullough
Summary: This article discusses the impact of nutrition, physical activity, and diet on recurrence and overall survival rates among cancer survivors. It provides evidence-based recommendations for cancer survivors and highlights the importance of addressing survivors' needs through clinical care coordination and resources.
CA-A CANCER JOURNAL FOR CLINICIANS
(2022)
Review
Oncology
William Sebastian, Lauren Forchette, Kelsey Donoughe, Yibei Lun, Anisha Verma, Tuoen Liu
Summary: In this review paper, various important aspects of hormone receptor (HR)-positive breast cancer were discussed, including HR structure and signaling, genetics (epigenetics and gene mutations), gene expression-based assays, traditional and new drugs for treatment, and new technological uses in diagnosis and treatment. Particularly, the commonly mutated genes and abnormally methylated genes in HR-positive breast cancer were summarized, and the common gene expression-based assays used in breast cancer as prognostic and/or predictive tools were compared in detail. These topic discussions have not been fully described and summarized within other research or review articles.
Article
Gastroenterology & Hepatology
Swati Pawa, Richard S. Kwon, Douglas S. Fishman, Nirav C. Thosani, Amandeep Shergill, Samir C. Grover, Mohammad Al-Haddad, Stuart K. Amateau, James L. Buxbaum, Audrey H. Calderwood, Jean M. Chalhoub, Nayantara Coelho-Prabhu, Madhav Desai, Sherif E. Elhanafi, Nauzer Forbes, Larissa L. Fujii-Lau, Divyanshoo R. Kohli, Jorge D. Machicado, Neil B. Marya, Wenly Ruan, Sunil G. Sheth, Andrew C. Storm, Nikhil R. Thiruvengadam, Bashar J. Qumseya
Summary: This clinical practice guideline provides an evidence based approach to prevent endoscopy-related injury (ERI) in GI endoscopists. It includes a detailed account of the methodology used for the evidence review and suggests various measures to decrease the risk of ERI.
GASTROINTESTINAL ENDOSCOPY
(2023)
